Don't Bank on Ebola

Welcome to John Ransom’s Stocks in the News where the headlines meet the trendlines.

Click here to listen to Ransom Notes Radio live or for archives of previous shows.

Stock number one: Becton, Dickinson and Company

Becton, Dickinson Signs $12.2B Deal to Acquire CareFusion-- Zacks

Becton, Dickinson and Company (BDX) entered into a mega $12.2 billion deal to acquire San Diego-based CareFusion Corporation (CFN) in an attempt to create a globally leading entity in the medication management and patient safety solutions market. The agreement, unanimously approved by the boards of both companies, marks the latest multibillion-dollar healthcare sector deal.

The combination of a large pile of cash from the stock sale and tepid growth of Yahoo's core business has investors circling. While Yahoo's share price has risen dramatically since Mayer took over, many analysts say that is largely because, until Alibaba went public last week, the only way investors could get a piece of that company was to buy Yahoo stock. Now they can buy Alibaba on the New York Stock Exchange.

Symbol: YHOO

Trailing PE: 36; Forward PE: 33

PEG: 3.16

Dividend: NA

Estimate Trend: Up

Ransom Note Trendline: Sell Yahoo

Stock number three: Chimerix

FDA greenlights emergency drug use for Ebola patients--CNBC

Some people suffering from Ebola may soon receive a drug that could help fight the deadly virus.

Biopharma company Chimerix said Monday that its drug brincidofovir has been approved for emergency use in treating Ebola patients,

The move, which the Food and Drug Administration signed off on, means that people suffering from the disease can be given the pill on a compassionate-use basis if doctors deem it suitable, the company said.

Brincidofovir joins two other experimental antiviral drugs that have already been deployed in the battle against Ebola.

Symbol: CMRX

Trailing PE: NA; Forward PE: NA

PEG: NA

Dividend: NA

Estimate Trend: NA

Ransom Note Trendline: Avoid Chimerix

Don't Bank on Ebola

Recommended